{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:40:13Z","timestamp":1772134813299,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In this cohort study, we determined time to blood pressure (BP) control and its predictors among hypertensive PLHIV enrolled in integrated hypertension-HIV care based on the World Health Organization (WHO) HEARTS strategy at Mulago Immunosuppression Clinic in Uganda. From August 2019 to March 2020, we enrolled hypertensive PLHIV aged\n                    <jats:inline-formula>\n                      <jats:alternatives>\n                        <jats:tex-math>$$\\ge$$<\/jats:tex-math>\n                        <mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                          <mml:mo>\u2265<\/mml:mo>\n                        <\/mml:math>\n                      <\/jats:alternatives>\n                    <\/jats:inline-formula>\n                    18 years and initiated Amlodipine 5\u2009mg mono-therapy for BP (140\u2013159)\/(90\u201399)\u2009mmHg or Amlodipine 5\u2009mg\/Valsartan 80\u2009mg duo-therapy for BP\u2009\u2265\u2009160\/90\u2009mmHg. Patients were followed with a treatment escalation plan until BP control, defined as BP\u2009&lt;\u2009140\/90\u2009mmHg. We used Cox proportional hazards models to identify predictors of time to BP control. Of 877 PLHIV enrolled (mean age 50.4 years, 62.1% female), 30% received mono-therapy and 70% received duo-therapy. In the monotherapy group, 66%, 88% and 96% attained BP control in the first, second and third months, respectively. For patients on duo-therapy, 56%, 83%, 88% and 90% achieved BP control in the first, second, third, and fourth months, respectively. In adjusted Cox proportional hazard analysis, higher systolic BP (aHR 0.995, 95% CI 0.989-0.999) and baseline ART tenofovir\/lamivudine\/efavirenz (aHR 0.764, 95% CI 0.637\u20130.917) were associated with longer time to BP control, while being on ART for &gt;10 years was associated with a shorter time to BP control (aHR 1.456, 95% CI 1.126\u20131.883). The WHO HEARTS strategy was effective at achieving timely BP control among PLHIV. Additionally, monotherapy anti-hypertensive treatment for stage I hypertension is a viable option to achieve BP control and limit pill burden in resource limited HIV care settings.\n                  <\/jats:p>","DOI":"10.1038\/s41371-024-00897-3","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T07:02:51Z","timestamp":1706770971000},"page":"452-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time to blood pressure control and predictors among patients receiving integrated treatment for hypertension and HIV based on an adapted WHO HEARTS implementation strategy at a large urban HIV clinic in Uganda"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4214-0206","authenticated-orcid":false,"given":"Willington","family":"Amutuhaire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred Collins","family":"Semitala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4024-1872","authenticated-orcid":false,"given":"Isaac Derick","family":"Kimera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-5526","authenticated-orcid":false,"given":"Christabellah","family":"Namugenyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Mulindwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Ssenyonjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodgers","family":"Katwesigye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Mugabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Mutungi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Ssinabulya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-2600","authenticated-orcid":false,"given":"Jeremy I.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne R.","family":"Katahoire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis S.","family":"Musoke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Yendewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris T.","family":"Longenecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4216-0083","authenticated-orcid":false,"given":"Martin","family":"Muddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"897_CR1","unstructured":"Global HIV & AIDS statistics \u2014 2020 fact sheet | UNAIDS [Internet]. https:\/\/www.unaids.org\/en\/resources\/fact-sheet Accessed 21 May 2021."},{"key":"897_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.15585\/mmwr.mm7112a2","volume":"71","author":"KA Fisher","year":"2022","unstructured":"Fisher KA, Patel SV, Mehta N, Stewart A, Medley A, Dokubo EK, et al. Lessons learned from programmatic gains in HIV service delivery during the COVID-19 Pandemic \u2014 41 PEPFAR-Supported Countries, 2020. Morb Mortal Wkly Rep. 2022;71:447\u201352.","journal-title":"Morb Mortal Wkly Rep."},{"key":"897_CR3","unstructured":"Global HIV Programme. Available from: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment. Accessed 10 Oct 2022."},{"key":"897_CR4","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/hiv.13077","volume":"22","author":"NA Jespersen","year":"2021","unstructured":"Jespersen NA, Axelsen F, Dollerup J, N\u00f8rgaard M, Larsen CS. The burden of non-communicable diseases and mortality in people living with HIV (PLHIV) in the pre-, early- and late-HAART era. HIV Med. 2021;22:478\u201390.","journal-title":"HIV Med"},{"key":"897_CR5","doi-asserted-by":"publisher","first-page":"010428","DOI":"10.7189\/jogh.09.010428","volume":"9","author":"M Haacker","year":"2019","unstructured":"Haacker M, B\u00e4rnighausen T, Atun R. HIV and the growing health burden from noncommunicable diseases in Botswana: modelling study. J Glob Health. 2019;9:010428.","journal-title":"J Glob Health"},{"key":"897_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-021-11698-5","volume":"21","author":"Z Yang","year":"2021","unstructured":"Yang Z, Zhu Z, Lizarondo L, Xing W, Han S, Hu H, et al. Experience of chronic noncommunicable disease in people living with HIV: a systematic review and meta-aggregation of qualitative studies. BMC Public Health. 2021;21:1\u201319.","journal-title":"BMC Public Health"},{"key":"897_CR7","unstructured":"A program of Resolve to Save Lives INTEGRATING HYPERTENSION AND HIV MANAGEMENT A practical Differentiated Service Delivery toolkit INTEGRATING HYPERTENSION AND HIV MANAGEMENT 2. [Online]. Available: https:\/\/www.resolvetosavelives.org."},{"key":"897_CR8","doi-asserted-by":"publisher","unstructured":"Unaids, Responding to the Challenge of Non-communicable Diseases, https:\/\/doi.org\/10.1097\/QAD.0000000000001888.","DOI":"10.1097\/QAD.0000000000001888"},{"key":"897_CR9","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1097\/QAD.0000000000001898","volume":"32","author":"S Vorkoper","year":"2018","unstructured":"Vorkoper S, Kupfer LE, Anand N, Patel P, Beecroft B, Tierney WM, et al. Building on the HIV chronic care platform to address noncommunicable diseases in sub-Saharan Africa: a research agenda. AIDS. 2018;32:S107\u201313.","journal-title":"AIDS"},{"key":"897_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5334\/ijic.5839","volume":"22","author":"G McCombe","year":"2022","unstructured":"McCombe G, Lim J, Van Hout MC, Lazarus JV, Bachmann M, Jaffar S, et al. Integrating care for diabetes and hypertension with HIV care in sub-saharan africa: a scoping review. Int J Integr Care. 2022;22:6.","journal-title":"Int J Integr Care"},{"key":"897_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25508","volume":"23","author":"A Kintu","year":"2020","unstructured":"Kintu A, Sando D, Okello S, Mutungi G, Guwatudde D, Menzies NA, et al. Integrating care for non-communicable diseases into routine HIV services: key considerations for policy design in sub-Saharan Africa. J Int AIDS Soc. 2020;23:e25508.","journal-title":"J Int AIDS Soc"},{"key":"897_CR12","unstructured":"https:\/\/www.escardio.org\/Education\/ESC-Education-by-Topic\/Hypertension Hypertension."},{"key":"897_CR13","unstructured":"The JNC 8 Hypertension Guidelines: An In-Depth Guide [Internet]. https:\/\/www.ajmc.com\/view\/the-jnc-8-hypertension-guidelines-an-in-depth-guide Accessed 10 Oct 2022."},{"key":"897_CR14","unstructured":"HEARTS: technical package for cardiovascular disease management in primary health care: Risk-based CVD management [Internet]. https:\/\/www.who.int\/publications\/i\/item\/9789240001367 Accessed 30 Nov 2022."},{"key":"897_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-022-08045-8","volume":"22","author":"M Muddu","year":"2022","unstructured":"Muddu M, Semitala FC, Kimera I, Mbuliro M, Ssennyonjo R, Kigozi SP, et al. Improved hypertension control at six months using an adapted WHO HEARTS-based implementation strategy at a large urban HIV clinic in Uganda. BMC Health Serv Res. 2022;22:1\u201314.","journal-title":"BMC Health Serv Res"},{"key":"897_CR16","doi-asserted-by":"publisher","first-page":"E35","DOI":"10.1161\/HYP.0000000000000087","volume":"73","author":"P Muntner","year":"2019","unstructured":"Muntner P, Shimbo D, Carey RM, Charleston JB, Gaillard T, Misra S, et al. Measurement of blood pressure in humans: a scientific statement from the american heart association. Hypertension. 2019;73:E35\u201366.","journal-title":"Hypertension"},{"key":"897_CR17","doi-asserted-by":"crossref","unstructured":"Kimera ID, Namugenyi C, Schwartz JI, Musimbaggo DJ, Ssenyonjo R, Atukunda P, et al. Integrated multi-month dispensing of antihypertensive and antiretroviral therapy to sustain hypertension and HIV control. J Hum Hypertens. 2023;37:213\u20139.","DOI":"10.1038\/s41371-022-00655-3"},{"key":"897_CR18","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1901113","volume":"380","author":"DB Ojji","year":"2019","unstructured":"Ojji DB, Mayosi B, Francis V, Badri M, Cornelius V, Smythe W, et al. Comparison of dual therapies for lowering blood pressure in black Africans. N. Engl J Med. 2019;380:2429\u201339.","journal-title":"N. Engl J Med"},{"key":"897_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/HYPERTENSIONAHA.118.10893","volume":"72","author":"SA Fahme","year":"2018","unstructured":"Fahme SA, Bloomfield GS, Peck R. Hypertension in HIV-infected adults. Hypertension. 2018;72:44\u201355.","journal-title":"Hypertension"},{"key":"897_CR20","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.jash.2017.06.004","volume":"11","author":"Y Xu","year":"2017","unstructured":"Xu Y, Chen X, Wang K. Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis. J Am Soc Hypertens. 2017;11:530\u201340.","journal-title":"J Am Soc Hypertens"},{"key":"897_CR21","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1093\/ofid\/ofx162.138","volume":"4","author":"P Ryscavage","year":"2017","unstructured":"Ryscavage P, Still W, Nyemba V, Stafford K. Prevalence of systemic hypertension among HIV-infected and HIV-uninfected young adults. Open Forum Infect Dis. 2017;4:S59\u2013S59.","journal-title":"Open Forum Infect Dis"},{"key":"897_CR22","doi-asserted-by":"publisher","first-page":"e004669","DOI":"10.1136\/bmjgh-2020-004669","volume":"6","author":"O Adeyemi","year":"2021","unstructured":"Adeyemi O, Lyons M, Njim T, Okebe J, Birungi J, Nana K, et al. Integration of non-communicable disease and HIV\/AIDS management: a review of healthcare policies and plans in East Africa. BMJ Glob Health. 2021;6:e004669.","journal-title":"BMJ Glob Health"},{"key":"897_CR23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290\u2013300.","journal-title":"Am J Med"},{"key":"897_CR24","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/HYPERTENSIONAHA.112.194167","volume":"59","author":"BM Egan","year":"2012","unstructured":"Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59:1124\u201331.","journal-title":"Hypertension"},{"key":"897_CR25","doi-asserted-by":"publisher","first-page":"NP485","DOI":"10.1177\/1010539512472361","volume":"27","author":"AT Cheong","year":"2015","unstructured":"Cheong AT, Mohd Said S, Muksan N. Time to achieve first blood pressure control after diagnosis among hypertensive patients at primary health care clinics: a preliminary study. Asia Pac J Public Health. 2015;27:NP485\u201394.","journal-title":"Asia Pac J Public Health"},{"key":"897_CR26","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","volume":"138","author":"ASV Shah","year":"2018","unstructured":"Shah ASV, Stelzle D, Ken Lee K, Beck EJ, Alam S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138:1100\u201312.","journal-title":"Circulation"},{"key":"897_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/jgid.jgid_4_18","volume":"11","author":"B Jarwani","year":"2019","unstructured":"Jarwani B. Cardiovascular disease and antiretroviral therapy. J Glob Infect Dis. 2019;11:91.","journal-title":"J Glob Infect Dis"},{"key":"897_CR28","doi-asserted-by":"publisher","first-page":"e59551","DOI":"10.1371\/journal.pone.0059551","volume":"8","author":"C Bavinger","year":"2013","unstructured":"Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, et al. Risk of cardiovascular disease from antiretroviral therapy for hiv: a systematic review. PLoS One. 2013;8:e59551.","journal-title":"PLoS One"},{"key":"897_CR29","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1177\/135965350501000706","volume":"10","author":"R Thi\u00e9baut","year":"2005","unstructured":"Thi\u00e9baut R, El-Sadr WM, Friis-M\u00f8ller N, Rickenbach M, Reiss P, Monforte AD, et al. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther. 2005;10:811\u201323.","journal-title":"Antivir Ther"},{"key":"897_CR30","unstructured":"Jackson IL, Lawrence SM, Igwe CN, Ukwe CV, Okonta MJ. Prevalence and control of hypertension among people living with HIV receiving care at a Nigerian hospital. PAMJ. 2022; 41:153."},{"key":"897_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-019-6838-6","volume":"19","author":"D Kwarisiima","year":"2019","unstructured":"Kwarisiima D, Atukunda M, Owaraganise A, Chamie G, Clark T, Kabami J, et al. Hypertension control in integrated HIV and chronic disease clinics in Uganda in the SEARCH study. BMC Public Health. 2019;19:1\u201310.","journal-title":"BMC Public Health"},{"key":"897_CR32","first-page":"47","volume":"10","author":"AT Debiso","year":"2020","unstructured":"Debiso AT, Debiso AT. Incidence and predictors of systemic hypertension among cohort of HIV\/AIDS infected patients in health facilities of South Ethiopia. Adv Infect Dis. 2020;10:47\u201363.","journal-title":"Adv Infect Dis"},{"key":"897_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/jhh.2015.97","volume":"30","author":"CU Nduka","year":"2016","unstructured":"Nduka CU, Stranges S, Sarki AM, Kimani PK, Uthman OA. Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: a systematic review with meta-analysis. J Hum Hypertens. 2016;30:355\u201362.","journal-title":"J Hum Hypertens"},{"key":"897_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm10030392","volume":"10","author":"BN Nkeh-Chungag","year":"2021","unstructured":"Nkeh-Chungag BN, Goswami N, Engwa GA, Sewani-Rusike CR, Mbombela V, Webster I, et al. Relationship between endothelial function, antiretroviral treatment and cardiovascular risk factors in hiv patients of african descent in South Africa: a cross-sectional study. J Clin Med. 2021;10:1\u201314.","journal-title":"J Clin Med"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-024-00897-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-024-00897-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-024-00897-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T10:03:41Z","timestamp":1715076221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-024-00897-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["897"],"URL":"https:\/\/doi.org\/10.1038\/s41371-024-00897-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2641141\/v1","asserted-by":"object"}]},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"25 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by The AIDS Support Organization (TASO) research ethics committee [Number: 040\/19\/Ug-REC-009], and the Uganda National Council of Science and Technology [HS 2644]. All study participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}